Alzamend Neuro Enters $25M Securities Purchase Agreement and Reports Nasdaq Non-Compliance

Alzamend Neuro, Inc.

Entered securities purchase agreement with Ault Lending for up to $25M in Series D convertible preferred stock; initial closing of $7.5M on July 31, 2026.
Notified Nasdaq of non-compliance with majority independent board standard following death of independent director Lynne Fahey McGrath on July 20, 2026; cure period until July 20, 2027.
Filed Series D Certificate of Designation with Delaware Secretary of State on July 31, 2026.
Purchaser Ault Lending is an affiliate of the Company; conversion price floor at $0.2668 per share.

item 1.01 item 3.01 item 3.02 item 5.03 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.